Bacteria from cheese may help cancer treatment overcome drug resistant cancerous cells


New research published in May 2023 showed the potential for probiotics to become an alternative treatment for drug resistant cancers. The research was conducted in Iran and focused on a common breast cancer drug, doxorubicin, which inhibits the ability of cancerous cells to grow. Over the course of treatment it has been revealed that cancer cells establish resistance to the drug and so researchers are eagerly looking for new anticancer agents.

This has lead to a new field of study that looks at the utilization of bio-therapeutics, such as probiotic bacteria, in this field of cancer treatment.

In this particular study, the researchers isolated and characterized lactic acid bacteria from traditional cheese. Then evaluated their activity against doxorubicin-resistant MCF-7 cells. One particular bacteria from cheese, Pediococcus acidilactici, was found to significantly reduce the viability of the resistant cells whilst being safe for normal cells.

These findings may accelerate the development of probiotics as promising alternative treatments to overcome drug-resistant cancers.

Read document in full:

Pediococcus acidilactici isolated from traditional cheese as a potential probiotic with cytotoxic activity against doxorubicin-resistant MCF-7 cells – Moj Khaleghi, Sadegh Khorrami & Tayebeh Jafari-Nasab
Department of Biology, Faculty of Sciences, Shahid Bahonar University of Kerman, Kerman, Iran




Browse Past Market Reports


Ingredient Solutions on Social Media


Tel: +353 29 76981 Fax: +353 29 76984

© Ingredient Solutions Ltd 2024 | All rights reserved